{
  "trial_id": "NCT01369069",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, baseline NIHSS score, pre-stroke modified Rankin Scale score, history of type 2 diabetes mellitus, admission blood glucose level, time from stroke symptom onset to randomization, time from hospital arrival to treatment initiation, prior use of IV tPA or IA therapies, presence of substantial pre-existing neurological or psychiatric illness, pregnancy status, renal dialysis status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Baseline NIHSS at randomization",
          "baseline NIHSS score"
        ],
        [
          "Medical History",
          "history of type 2 diabetes mellitus"
        ],
        [
          "Eligibility POC blood glucose (mg/dL)",
          "admission blood glucose level"
        ],
        [
          "Thrombolysis or Thrombectomy",
          "prior use of IV tPA or IA therapies"
        ],
        [
          "Final diagnosis",
          "presence of substantial pre-existing neurological or psychiatric illness"
        ],
        [
          "Pregnancy status",
          "pregnancy status"
        ],
        [
          "Renal dialysis status",
          "renal dialysis status"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Baseline NIHSS category at randomization"
      ],
      "remaining_candidate_features": [
        "pre-stroke modified Rankin Scale score",
        "time from stroke symptom onset to randomization",
        "time from hospital arrival to treatment initiation"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Baseline NIHSS score, Pre-stroke modified Rankin Scale score, History of type 2 diabetes mellitus, Admission blood glucose, Time from stroke symptom onset to randomization, Use of IV tPA or IA therapies,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Baseline NIHSS at randomization",
          "Baseline NIHSS score"
        ],
        [
          "Eligibility POC blood glucose (mg/dL)",
          "Admission blood glucose"
        ],
        [
          "Thrombolysis or Thrombectomy",
          "Use of IV tPA or IA therapies"
        ],
        [
          "Medical History",
          "History of type 2 diabetes mellitus"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Final diagnosis",
        "Baseline NIHSS category at randomization"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "Pre-stroke modified Rankin Scale score",
        "Time from stroke symptom onset to randomization"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, History of Diabetes, Admission Blood Glucose, Baseline NIHSS Score, Pre-stroke Modified Rankin Scale Score, Body Temperature, Systolic Blood Pressure, Diastolic Blood Pressure, Heart Rate.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Medical History",
          "History of Diabetes"
        ],
        [
          "Eligibility POC blood glucose (mg/dL)",
          "Admission Blood Glucose"
        ],
        [
          "Baseline NIHSS at randomization",
          "Baseline NIHSS Score"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Final diagnosis",
        "Thrombolysis or Thrombectomy",
        "Baseline NIHSS category at randomization"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "Pre-stroke Modified Rankin Scale Score",
        "Body Temperature",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "Heart Rate"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, weight, height, body mass index (BMI), history of type 2 diabetes mellitus, admission blood glucose, baseline NIHSS score, pre-stroke modified Rankin Scale score, time of symptom onset, time of hospital arrival, time of randomization, IV tPA or IA tPA use, IA therapies use.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "Medical History",
          "history of type 2 diabetes mellitus"
        ],
        [
          "Eligibility POC blood glucose (mg/dL)",
          "admission blood glucose"
        ],
        [
          "Baseline NIHSS at randomization",
          "baseline NIHSS score"
        ],
        [
          "Thrombolysis or Thrombectomy",
          "IV tPA or IA tPA use"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Final diagnosis",
        "Baseline NIHSS category at randomization"
      ],
      "remaining_candidate_features": [
        "weight",
        "height",
        "body mass index (BMI)",
        "pre-stroke modified Rankin Scale score",
        "time of symptom onset",
        "time of hospital arrival",
        "time of randomization",
        "IA therapies use."
      ]
    }
  }
}